Indications for Antiarrhythmic Therapy: A Wealth of Controversy, A Dearth of Data
Authors: RAYMOND L. WOOSLEY
Journal: Annals of Internal Medicine (1988)

Editorials1 March 1988Indications for Antiarrhythmic Therapy: A Wealth of Controversy, A Dearth of DataRAYMOND L. WOOSLEY, M.D., Ph.D.RAYMOND L. WOOSLEY, M.D., Ph.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-3-450 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptFew situations in medicine are comparable to that involving antiarrhythmic drugs, in which so many potentially toxic agents are given to so many patients without proof of benefit. Will using this class of drugs parallel the experience with antihypertensives, for example, or will they pass into antiquity with practices like treatment of fever with purgatives? For years, physicians prescribed antihypertensives with the hope that control of this risk factor would improve mortality. We now know that control of severe hypertension by any means provides clinical benefit by reducing the incidence of stroke, myocardial infarction, and renal failure (1, 2). However,...References1. . Effects of treatment on morbidity in hypertension I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-34. CrossrefMedlineGoogle Scholar2. . Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-52. CrossrefMedlineGoogle Scholar3. . Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1986;58:1-13. CrossrefMedlineGoogle Scholar4. MASONWINKLE JR. Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation. 1978;58:971-85. CrossrefMedlineGoogle Scholar5. RUSKINSCHOENFELDGARAN JMH. Role of electrophysiologic techniques in the selection of antiarrhythmic drug regimens for ventricular arrhythmias. Am J Cardiol. 1983;52:41C-6C. CrossrefMedlineGoogle Scholar6. . The Cardiac Arrhythmia Pilot Study. Am J Cardiol. 1986;57:91-5. CrossrefMedlineGoogle Scholar7. ROKSETHSTORSTEIN RO. Quinidine therapy of chronic auricular fibrillation: the occurrence and mechanism of syncope. Arch Intern Med. 1963;111:184-9. CrossrefMedlineGoogle Scholar8. HARRISON D. Should lidocaine be administered routinely to all patients after acute myocardial infarction? Circulation. 1978;58:581-4. CrossrefMedlineGoogle Scholar9. LIEWEILENSVAN CAPELLEDURRER KHFD. Lidocaine in the prevention of primary ventricular fibrillation: a double-blind, randomized study of 212 consecutive patients. N Engl J Med. 1974;291:1324-6. CrossrefMedlineGoogle Scholar10. DESILVAHENNEKENSLOWNCASSCELLS RCBW. Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomized trials. Lancet. 1981;2:855-8. CrossrefMedlineGoogle Scholar11. WYMANSLAUGHTERFAROLINO MRD. Multiple bolus technique for lidocaine administration in acute ischemic heart disease. II. Treatment of refractory ventricular arrhythmias and the pharmacokinetic significance of severe left ventricular failure. J Am Coll Cardiol. 1983;2:764-9. CrossrefMedlineGoogle Scholar12. FURBERG C. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol. 1983;52:32C-6C. CrossrefMedlineGoogle Scholar13. BIGGERWELDROLNITZKY JFL. Prevalence, characteristics and significance of ventricular tachycardia (three or more complexes) detected with ambulatory electrocardiographic recording in the late hospital phase of acute myocardial infarction. Am J Cardiol. 1981;48:815-23. CrossrefMedlineGoogle Scholar14. MORGANROTH J. Premature ventricular complexes: diagnosis and indications for therapy. JAMA. 1984;252:673-6. CrossrefMedlineGoogle Scholar15. VLAY S. How the university cardiologist treats ventricular premature beats: a nationwide survey of 65 University Medical Centers. Am Heart J. 1985;110:904-12. CrossrefMedlineGoogle Scholar16. . The effect of encainide, flecainide, Imipramine, and moricizine on ventricular arrhythmias occurring 6 to 60 days after myocardial infarction: results of a randomized double-blind, multicenter trial. Am J Cardiol. 1988; [In press]. Google Scholar17. LOWNWOLF BM. Approaches to sudden death from coronary heart disease. Circulation. 1971;44:130-42. CrossrefMedlineGoogle Scholar18. . The prognostic importance of premature ventricular complexes in the last post-infarction period. Experience in the Coronary Drug Project. Acta Cardiol (Brux). 1974;18:(suppl) 33-53. MedlineGoogle Scholar19. CONAN DOYLE A. A Scandal in Bohemia. In: The Illustrated Sherlock Holmes Treasury—The Adventures of Sherlock Holmes. New York: Avenel/Crown; 1976:3. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTime to arrhythmic, ischemic, and heart failure events: Exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression TrialOrg 7797: A New and Unusual Antiarrhythmic AgentClinical evaluation of bidisomide, a new class I antiarrhythmic: Initial intravenous dose-finding studyLong-Term follow-up in patients with incessant ventricular tachycardiaSpontaneous variability in ventricular ectopic activity during chronic antiarrhythmic therapy.Use of Ambulatory Electrocardiographic (Holter) MonitoringJohn P. DiMarco, MD, PhD, John T. Philbrick, MDAntiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardiaNewer aspects of antiarrhythmic drug development: IntroductionEffectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugsPrevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: A dangerous imbalance in the risk-benefit ratioAcute myocardial infarction 1 March 1988Volume 108, Issue 3Page: 450-452KeywordsAntihypertensivesDrug therapyDrugsFeversHypertensionMedical risk factorsMortalityMyocardial infarctionRenal failureToxic agents Issue Published: 1 March 1988 PDF DownloadLoading ...